A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands

Simone Claudiani, Jeroen J. W. M. Janssen, Jenny Byrne, Graeme Smith, Nicole Blijlevens, Manoj Raghavan, Matthew Smith, Richard E. Clark, Susan Mclain-Smith, Angela M. Carter, Dragana Milojkovic, Jane F. Apperley

Research output: Contribution to journalArticleAcademicpeer-review


Objectives: To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML). Methods: This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands. Results: Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 months. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major molecular response rates in CP patients were 67% and 55%, respectively. After a median follow-up of 21.5 months, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2 years postbosutinib initiation were 95% and 91%, respectively. Overall, 33/87 (38%) patients discontinued bosutinib due to either lack of efficacy/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty-two (94%) patients experienced ≥1 adverse event possibly related to bosutinib, most commonly diarrhea (52%). Conclusions: Bosutinib used in routine clinical practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable.
Original languageEnglish
Pages (from-to)90-99
Number of pages10
JournalEuropean journal of haematology
Issue number1
Publication statusPublished - 1 Jul 2022


  • bosutinib
  • chronic myeloid leukemia
  • retrospective studies
  • tyrosine kinase inhibitor

Cite this